Two complexes localize to the central spindle and regulate completion of cytokinesis: one, centralspindlin, contains a kinesin-like protein and a Rhofamily GAP; the second contains Aurora B kinase. Aurora B kinase is known to regulate localization of centralspindlin and may regulate the activity of the RhoGAP component of centralspindlin.
Recently, a fourth approach has been enlisted, using selective kinase inhibitors to inhibit Aurora B in mammalian cells [11, 12] . These studies confirm and significantly extend our understanding of the role of Aurora B in biorientation of sister kinetochores and in regulation of the spindle assembly checkpoint. The localization of the centralspindlin complex and central spindle assembly were found to be defective in cells in which Aurora B kinase activity is pharmacologically inhibited [11] . Thus, it appears that Aurora B probably has a conserved role in central spindle assembly. It is conceivable that some of the weaker phenotypes described earlier resulted from partial inhibition of the kinase or difficulties in identifying anaphase cells among highly affected cells in asynchronous cultures.
Both the centralspindlin complex and the Aurora B kinase complex localize to the central spindle, albeit with some differences, centralspindlin being more restricted to the center of the structure [2] . Given the partially overlapping distribution of these complexes, it is attractive to consider that Aurora B might directly regulate the centralspindlin complex. A recent paper by Minoshima et al. Minoshima et al. [13] found that recombinant Aurora B kinase -in the absence of its associated subunits, which are known to regulate Aurora B kinase activity -can phosphorylate MgcRacGAP. They found that Aurora B could phosphorylate a fragment of MgcRacGAP containing the GAP domain, though this was not the best substrate among the fragments of the protein tested. Minoshima et al. [13] then tested whether this phosphorylation event altered the ability of MgcRacGAP to activate GTP hydrolysis by RhoA and Rac. Interestingly, addition of Aurora B kinase -but not a catalytically inactive mutant -increased the GAP activity of MgcRacGAP towards RhoA, though the activity against Rac and Cdc42 appeared unaltered.
The MgcRacGAP phosphorylation site was assessed using small peptides containing potential sites as substrates, and one site, serine 387, seemed to be a substrate for Aurora B. To substantiate these results, Minoshima et al. [13] substituted a phosphomimetic residue, aspartic acid, at potential phosphorylation sites. They observed that an aspartic acid at position 387 somewhat activated the GAP activity versus RhoA; moreover, this substitution greatly reduced the GAP activity towards Rac. As an in vivo test of the importance of modification of this site, the authors showed that overexpression of the mutant version carrying an alanine substitution at position 387 caused cytokinesis defects, whereas an aspartic acid substitution did not. Minoshima et al. [13] conclude that phosphorylation of this site switches the specificity of this RhoGAP from Rac to RhoA. They propose that RhoAspecific GAP activity would be locally activated at the midbody to inactivate RhoA and promote completion of cytokinesis. These data are potentially exciting as phosphoregulation of RhoGAP substrate specificity has not been observed previously.
These data should, however, be considered in light of the crystal structures of a RhoGAP in a complex with Rho family GTPases. The structure of the GAP domain of p50 RhoGAP has been solved in the ground state with Cdc42 and in conformations that are thought to reflect the transition state with RhoA and Cdc42 [16] [17] [18] . These structures have shown that GAP domains induce GTP hydrolysis by positioning a basic residue -the so-called arginine finger (arginine 305 in p50) -next to the oxygen that bridges the β β and γ γ phosphate groups of GTP, thereby stabilizing the negative charge that develops during hydrolysis. Serine 307, which corresponds to serine 387 in MgcRacGAP, is also located at the RhoGAP-Rho interface ( Figure 1A ). In the transition state, serine 307 is in a small pocket lined by invariant residues, in particular it is sandwiched by glycine 14 in the P-loop and glutamate 64 in switch II region of RhoA ( Figure 1B) . In the ground state, serine 307 is less deeply engaged in this pocket, but it remains in contact with the other residues that form this pocket. The structural conservation of these loops is underscored by the way it is possible to engineer constitutively active derivatives of the vast majority of small GTPases by mutating the residues that correspond to glycine 14 or glutamine 63 of RhoA. Phosphorylation of serine 307 would therefore be predicted to similarly affect the interaction between the GAP domain and Rac and Rho, rather than increasing its activity towards RhoA and decreasing its activity towards Rac. It is surprising, therefore, that Minoshima et al. [13] found replacement of serine 387 by aspartic acid dramatically reduced its RacGAP activity and appeared to slightly increase its RhoGAP activity.
If regulation of CYK-4/MgcRacGAP by Aurora B is a conserved regulatory mechanism, then this phosphorylation site ought to be conserved. Although the GAP domain is well conserved among CYK-4 orthologs, the equivalent of serine 387 is substituted by a proline residue in C. elegans CYK-4 ( Figure 1C ). In fact, this residue is variable in RhoGAPs, but it is usually a residue with a small side chain. The lack of consistency between the effect of phosphorylation by Aurora B and the replacement of serine 387 with a negatively charged residue also suggests that this model might need revision.
How can these observations be rationalized? One possibility is that MgcRacGAP may have structural differences that preclude extrapolating from the structures of p50 bound to RhoA or Cdc42. Alternatively, the effect of Aurora B kinase on the RhoGAP activity of MgcRac-GAP may be due to phosphorylation of MgcRacGAP at a site distinct from serine 387. This could have been tested simply by assessing whether Aurora kinase stimulates the GAP activity of a MgcRacGAP mutant in which serine 387 has been replaced by alanine. At this juncture, regulation of the GAP activity of CYK-4/MgcRacGAP by Aurora B is an interesting possibility that requires further experimentation.
